GB201702582D0 - Screening method - Google Patents

Screening method

Info

Publication number
GB201702582D0
GB201702582D0 GBGB1702582.6A GB201702582A GB201702582D0 GB 201702582 D0 GB201702582 D0 GB 201702582D0 GB 201702582 A GB201702582 A GB 201702582A GB 201702582 D0 GB201702582 D0 GB 201702582D0
Authority
GB
United Kingdom
Prior art keywords
screening method
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1702582.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Brookes University
Original Assignee
Oxford Brookes University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Brookes University filed Critical Oxford Brookes University
Priority to GBGB1702582.6A priority Critical patent/GB201702582D0/en
Publication of GB201702582D0 publication Critical patent/GB201702582D0/en
Priority to PCT/GB2018/050411 priority patent/WO2018150188A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB1702582.6A 2017-02-17 2017-02-17 Screening method Ceased GB201702582D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1702582.6A GB201702582D0 (en) 2017-02-17 2017-02-17 Screening method
PCT/GB2018/050411 WO2018150188A1 (en) 2017-02-17 2018-02-16 Screening method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1702582.6A GB201702582D0 (en) 2017-02-17 2017-02-17 Screening method

Publications (1)

Publication Number Publication Date
GB201702582D0 true GB201702582D0 (en) 2017-04-05

Family

ID=58486839

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1702582.6A Ceased GB201702582D0 (en) 2017-02-17 2017-02-17 Screening method

Country Status (2)

Country Link
GB (1) GB201702582D0 (en)
WO (1) WO2018150188A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064770A2 (en) * 2003-01-17 2004-08-05 Government Of The United States Of America As Represented By The Secretary, Department Of Health Andhuman Services Use of smad3 inhibitor in the treatment of fibrosis dependent on epithelial to mesenchymal transition as in the eye and kidney
WO2010099363A1 (en) * 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20110143960A1 (en) * 2009-12-10 2011-06-16 Labarbera Daniel V 3d-models for high-throughput screening drug discovery and development
TW201619375A (en) * 2014-09-25 2016-06-01 日產化學工業股份有限公司 Screening method of anticancer agent
KR20160083742A (en) * 2015-01-02 2016-07-12 재단법인 의약바이오컨버젼스연구단 Method for screening EMT inhibitor
JP7057557B2 (en) * 2015-07-31 2022-04-20 国立大学法人大阪大学 Methods for assessing therapeutic and / or preventive efficacy against epithelial diseases, screening methods for therapeutic agents for epithelial diseases, and therapeutic agents for epithelial diseases

Also Published As

Publication number Publication date
WO2018150188A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
GB201701109D0 (en) Method
EP3469376C0 (en) Screening method
GB201704847D0 (en) Callibration method
GB201710815D0 (en) Method
GB201706778D0 (en) Method
GB201709333D0 (en) Method
GB201706544D0 (en) Method
GB201700352D0 (en) Method
EP3720940C0 (en) Parts-washing method
GB201711066D0 (en) Method
GB201710812D0 (en) Method
GB201702250D0 (en) Method
GB201709387D0 (en) Method
GB201708853D0 (en) Method
GB201707140D0 (en) Method
EP3627152A4 (en) Screening method
GB201705897D0 (en) Method
GB201704536D0 (en) Method
GB201702096D0 (en) Method
GB201701941D0 (en) Method
GB201702924D0 (en) Screening method
GB201702582D0 (en) Screening method
GB201804489D0 (en) Screening method
GB201800632D0 (en) Screening method
GB201619812D0 (en) Screening Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)